Delving into the Latest Updates on BioGate Precision Medicine Corp. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Endocrinology and Metabolic Disease

Biological products

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	2
Neoplasms	2

Top 5 Drug Type	Count

Biological products	1
Monoclonal antibody	1

Top 5 Target	Count

PTHrP(parathyroid hormone like hormone)	1

AbstractAlthough approximately 35% of approved drugs target G-protein-coupled receptors (GPCRs), cancer-specific GPCR-targeted therapies remain limited. Notably, several GPCRs and their ligands, including parathyroid hormone-related protein (PTHrP), are overexpressed in various solid tumors, including pancreatic cancer. In about 30% of pancreatic cancer cases, the PTHLH gene is co-amplified with the KRAS oncogene on chromosome 12, a phenomenon also observed in lung and colorectal cancers. Furthermore, the PTHLH gene can drive cancer progression through self-amplification. To address this, BioGate has developed BGM-2121, a potent humanized IgG1 monoclonal antibody targeting the N-terminal region (a.a. 1-34) of PTHrP, aiming to treat pancreatic cancer by targeting the PTHrP/PTH1R pathway. Preclinical studies have confirmed the specificity and antitumor activity of BGM-2121. In vitro assays demonstrated the antibody's high affinity and specificity for PTHrP, while in vivo animal studies using human pancreatic cancer cell models in mice showed significant antitumor activity. Notably, BGM-2121 effectively reduced tumor growth, halted disease progression in mouse models, and significantly extended survival. Additionally, in lung squamous cell carcinoma models, BGM-2121 successfully prevented and even reversed hypercalcemia and weight loss—key contributors to humoral hypercalcemia of malignancy (HHM) and cancer cachexia in human patients. Comprehensive safety and pharmacokinetic (PK) studies, including toxicokinetics (TK) and GLP-compliant repeated-dose toxicity studies, have thoroughly evaluated the safety profile of BGM-2121. In conclusion, this potent PTHrP-targeting antibody shows considerable promise as a therapeutic agent for cancers with PTHrP overexpression (e.g., pancreatic and lung cancers), humoral hypercalcemia of malignancy, and PTHrP-mediated cancer cachexia. We are currently preparing to submit an Investigational New Drug (IND) application to the TFDA and plan to initiate clinical trials to evaluate its potential as a novel biologic treatment for hard-to-treat metastatic cancers in Taiwan.Citation Format:Chiawen Ho, Chi-Feng Tseng, Chong-Jen Huang. A potent therapeutic antibody BGM-2121 targeting parathyroid hormone-related peptide (PTHrP) for pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2124.

1

News (Medical) associated with BioGate Precision Medicine Corp.

07 Mar 2024

·www.prnewswire.com

A Global Milestone in Innovative Pancreatic Cancer Therapy

Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate. TAIPEI, March 6, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a member of Powerchip Group, held a press conference today to unveil an innovative breakthrough in pancreatic cancer drug development. Dr. Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through in-house R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology. Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for TFDA Phase I clinical trials and to seek approval from the U.S. FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide. Continue Reading Pancreatic cancer affects 500,000 people globally each year, with over 3,000 cases in Taiwan annually. It is difficult to diagnose early due to its inconspicuous initial symptoms, so most patients are diagnosed at advanced stages. According to the latest statistics from the National Institutes of Health (NIH) in the United States, the five-year survival rate for pancreatic cancer with distant metastasis is only 3.2%, making it the deadliest cancer. Current treatments primarily involve chemotherapy combinations, such as Paclitaxel and Gemcitabine. However, these treatments have significant side effects, including high hematological toxicity, anemia, leukemia, platelet reduction, nausea, peripheral neuropathy and anorexia. Sadly, most patients experience a survival period of only 6 to 8 months after diagnosis, highlighting the suboptimal treatment outcomes. In contrast, BioGate's targeted therapy biologic agent BGX, can block intracellular signal transmission to inhibit cell proliferation and spread in stage II to IV pancreatic cancer. In studies of animals implanted with human cancer cells, BGX successfully inhibited the growth and spread of pancreatic cancer cells and prolonged survival rates. Unlike chemotherapy, BGX is non-invasive and has very low toxicity, offering hope for improved quality of life and increased life expectancy for pancreatic cancer patients worldwide. Looking forward, Dr. Huang revealed that BioGate's groundbreaking targeted therapy biologic agent BGX not only advances pancreatic cancer research, but also holds promise for treating other type of cancers such as lung, colorectal, esophageal, gallbladder, stomach, breast, and prostate cancers. BioGate will continue the research and development of new drugs for treating cancers and malignant diseases caused by cancers such as cachexia, thereby expanding the company's future potential. Dr. Huang emphasized BioGate's commitment to visionary breakthroughs and in-house innovation. Additionally, BioGate actively seeks strategic partnerships across industry, academia, and research sectors, collaborating with international pharmaceutical companies to jointly develop new drugs and conduct clinical trials. These efforts aim to explore international markets and enhance BioGate's operational capabilities and corporate value. CONTACT: Vicky Chang, vicky@ir-trust.tw SOURCE BioGate Precision Medicine Corp.

Phase 1ImmunotherapyIND

100 Deals associated with BioGate Precision Medicine Corp.

Login to view more data

100 Translational Medicine associated with BioGate Precision Medicine Corp.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

Login to view more data